Alitretinoin therapy for palmoplantar pustulosis

Abstract

We read with interest the RCT by Reich et al., and we found that the conclusion given: "this study provided no evidence to support further exploration of alitretinoin in the treatment of severe palmoplantar pustulosis (PPP)" should be carefully interpreted.¹ The authors found no significant difference in the percentage change in PPPASI between the alitretinoin (45.2% ±32.8 of improvement) and placebo (44.6%, ±45.9), 95% CI rate difference -31% to 32%.¹

This article is protected by copyright. All rights reserved.

http://ift.tt/2q8fpDI